Neurogene Inc. Price & Performance (NGNE)

Neurogene has finalized its merger with Neoleukin Therapeutics, resulting in a combined entity with nearly $200 million in cash. The deal included an oversubscribed $95 million private placement, positioning the company to advance its gene therapy pipeline and fund operations into the second half of 2026.123

Neurogene’s latest financial report shows a significant increase in assets and cash following its merger with Neoleukin. Net losses widened due to merger-related costs, but the company’s strengthened balance sheet is expected to support ongoing clinical trials and research, particularly in gene therapy for rare neurological diseases.456

Neurogene announced successful initial dosing of two patients in its NGN-401 Rett syndrome trial, with no serious adverse events reported. Interim clinical data are expected later this year, and investor confidence is buoyed by the company’s robust funding and proprietary EXACT gene therapy technology.37